Breaking News
Get 50% Off 0
🏄 Grow your portfolio even on vacation with InvestingPro | Summer Sale 50% OFF
CLAIM SALE
Close

4D Molecular Therapeutics Inc (FDMT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow 4D Molecular's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
7.09 +0.24    +3.50%
22/08 - Closed. Currency in USD
After Hours
7.01
-0.08
-1.13%
0:28:15 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 447,810
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 6.88 - 7.33
4D Molecular 7.09 +0.24 +3.50%

4D Molecular Therapeutics Inc Company Profile

 
Get an in-depth profile of 4D Molecular Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

227

Equity Type

ORD

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.

Contact Information

Address 5858 Horton Street Suite 455
EmeryVille, 94608
United States
Phone 510 505 2680
Fax -

Top Executives

Name Age Since Title
Jacob M. Chacko 43 2019 Independent Director
Ronal Crystal - 2023 Member of Scientific Advisory Board
Shawn Cline Tomasello 65 2020 Independent Director
Susannah Gray 63 2020 Independent Director
Charles P. Theuer 60 2015 Independent Director
Nancy B. Miller-Rich 65 2020 Independent Director
Arshad M. Khanani - 2024 Chair of Ophthalmology Advisory Board
David H. Kirn 62 2013 Co-Founder, CEO & Director
John F. Milligan 64 2020 Executive Chairman
Noriyuki Kasahara 62 2022 Member of Scientific Advisory Board
Paul J. Utz - 2023 Member of Scientific Advisory Board
Wenchao Song - 2024 Member of Scientific Advisory Board
Anat Loewenstein - 2024 Member of Ophthalmology Advisory Board
Frank G. Holz - 2024 Member of Ophthalmology Advisory Board
Dante Pieramici - 2024 Member of Ophthalmology Advisory Board
Douglas Hanahan - - Member of the Scientific Advisory Board
Richard B. Moss - 2023 Member of Scientific Advisory Board
Amy Rosenberg - 2023 Member of Scientific Advisory Board
Amit Gaggar - 2023 Member of Scientific Advisory Board
David S. Boyer - 2024 Member of Ophthalmology Advisory Board
Napoleone Ferrara 68 2024 Member of Scientific Advisory Board
Ronald G. Crystal - - Member of the Scientific Advisory Board
John P. Atkinson - 2024 Member of Scientific Advisory Board
Patricio G. Schlottmann - 2024 Member of Ophthalmology Advisory Board
Gemmy Cheung - 2024 Member of Ophthalmology Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

FDMT Comments

Write your thoughts about 4D Molecular Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email